Enliven Therapeutics Inc. Common Stock (ELVN)

FairStock Score: 23/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham investor, I start with durable earning power and a margin of safety. Enliven has neither today. It is a clinical-stage biopharma with no revenue in any filed period. In fiscal Q2 2026, the quarter ended 2026-06-30, net income was $-32.5 million and diluted EPS was $-0.49. Full-year FY2025 net loss was $-103.7 million, worse than FY2024's $-89.0 million and FY2023's $-71.6 million. That is the opposite of compounding earnings. Trailing free cash flow is $-67.0 million and the FairStock FCF yield is -2.3%. The balance sheet shows no debt, with D/E of 0.00 and an Altman Z-Score of 115.73, but a Piotroski F-Score of 1/9 and FairStock Score of 23/100 tell me the financial quality is thin. The company's moat is unproven: two Phase 1 candidates, ELVN-001 for chronic myeloid leukemia and ELVN-002 for HER2-driven cancers, are potential options, not established franchises. At the 2026-10-13 close of $39.49, market cap is $2.9 billion; P/B is 3.23 and P/E is -23.93. Without revenue or profits, Graham-style valuation cannot anchor the price; it rests on clinical probability. Beta of 0.24 and a 52-week range of $14.78 to $62.32 show the stock can move on trial news. Growth trajectory is really a cash-burn trajectory until data change it. I see a speculative biotech, not a business with a margin of safety.

In plain English: Enliven Therapeutics is a testing-stage cancer drug company with two experimental medicines and no product sales yet. It has lost money for years and used about $67 million in cash over the last twelve months, so the business is not yet strong by normal financial measures. At the 2026-10-13 close of $39.49 and a $2.9 billion value, the price mostly reflects hopes for future trial results rather than today's numbers, so it is hard to call cheap or fairly priced on current results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer